Hamm CW - Search Results

1

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.

Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C, Hamm CW, Robbins MA, Kleiman NS, Théroux P, White HD, Topol EJ. Roffi M, et al. Among authors: hamm cw. Eur Heart J. 2002 Sep;23(18):1441-8. doi: 10.1053/euhj.2002.3160. Eur Heart J. 2002. PMID: 12208224

2

Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.

Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Valgimigli M, et al. Eur Heart J. 2010 Jan;31(1):35-49. doi: 10.1093/eurheartj/ehp376. Epub 2009 Sep 14. Eur Heart J. 2010. PMID: 19755402 Review.

3

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.

Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Heeschen C, et al. Among authors: hamm cw. Lancet. 1999 Nov 20;354(9192):1757-62. doi: 10.1016/s0140-6736(99)10285-x. Lancet. 1999. PMID: 10577636 Clinical Trial.

4

Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists.

Heeschen C, Hamm CW. Heeschen C, et al. Among authors: hamm cw. Lancet. 2000 Jan 29;355(9201):330-1. doi: 10.1016/S0140-6736(99)00464-X. Lancet. 2000. PMID: 10665546 No abstract available.

5

Cardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status.

Heeschen C, Goldmann BU, Terres W, Hamm CW. Heeschen C, et al. Among authors: hamm cw. Eur Heart J. 2000 Jul;21(14):1159-66. doi: 10.1053/euhj.1999.1986. Eur Heart J. 2000. PMID: 10924299

6

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.

Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ. Roffi M, et al. Among authors: hamm cw. Circulation. 2001 Dec 4;104(23):2767-71. doi: 10.1161/hc4801.100029. Circulation. 2001. PMID: 11733392

7

Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study.

Brener SJ, Moliterno DJ, Aylward PE, van't Hof AW, Ruźyllo W, O'Neill WW, Hamm CW, Westerhout CM, Granger CB, Armstrong PW; APEX-AMI Investigators. Brener SJ, et al. Among authors: hamm cw. Eur Heart J. 2008 May;29(9):1127-35. doi: 10.1093/eurheartj/ehn125. Epub 2008 Mar 27. Eur Heart J. 2008. PMID: 18375399

8

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.

Stone GW, Généreux P, Harrington RA, White HD, Gibson CM, Steg PG, Hamm CW, Mahaffey KW, Price MJ, Prats J, Deliargyris EN, Bhatt DL. Stone GW, et al. Among authors: hamm cw. Eur Heart J. 2018 Dec 7;39(46):4112-4121. doi: 10.1093/eurheartj/ehy562. Eur Heart J. 2018. PMID: 30203006 Free PMC article. Clinical Trial.

9

Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.

Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, Stone GW, Cohen DJ, Moliterno DJ. Casserly IP, et al. Am J Cardiol. 2003 Jul 15;92(2):125-9. doi: 10.1016/s0002-9149(03)00525-3. Am J Cardiol. 2003. PMID: 12860211 Clinical Trial.

10

Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.

Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm C, Price MJ, Prats J, Elkin S, Deliargyris EN, White HD, Menozzi A, Harrington RA, Bhatt DL; MPH on Behalf of the CHAMPION PHOENIX Investigators. Abtan J, et al. Int J Cardiol. 2019 Mar 1;278:217-222. doi: 10.1016/j.ijcard.2018.11.114. Epub 2018 Nov 23. Int J Cardiol. 2019. PMID: 30563770 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

731 results

Search Page